CFA
VYGR icon

Carroll Financial Associates’s Voyager Therapeutics VYGR Stock Holding History

Carroll Financial Associates’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100
Closed -$1K – 1695
2020
Q2 		$1K Hold
100
– – ﹤0.01% 1472
2020
Q1 		$0 Hold
100
– – ﹤0.01% 1694
2019
Q4 		$1K Hold
100
– – ﹤0.01% 1485
2019
Q3 		$1K Buy
+100
New +$2.1K ﹤0.01% 1465

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carroll Financial Associates's VYGR Position: Q3 2020 in Review

Carroll Financial Associates sold out of Voyager Therapeutics (VYGR) in Q3 2020, closing a stake of 100 shares — an estimated $1K sold.

Carroll Financial Associates first reported a position in VYGR in Q3 2019 and held it in 4 quarters. The position peaked at $1K in Q2 2020. 110 funds tracked by Wall St. Rank hold VYGR as of Q3 2020.

  • Carroll Financial Associates reported no remaining Voyager Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Carroll Financial Associates sold 100 Voyager Therapeutics shares in Q3 2020, an estimated $1K.
  • Carroll Financial Associates first reported a position in Voyager Therapeutics in Q3 2019 and held it in 4 quarters.
  • Carroll Financial Associates's Voyager Therapeutics position peaked at $1K in Q2 2020.
  • 110 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2020.

Based on Carroll Financial Associates's 13F filing for Q3 2020, filed 6 Oct 2020.